ישראל - עברית - Ministry of Health

teva israel ltd - tranexamic acid - טבליה - tranexamic acid 500 mg - tranexamic acid - tranexamic acid - treatment of hemorrhage occuring in some forms of surgery, including prostatectomy. hematuria. menorrhagia. hereditary angioneurotic edema.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 1 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 2 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novo nordisk ltd., israel - eptacog alfa (activated) - אבקה להכנת תמיסה לזריקה - eptacog alfa (activated) 5 mg/vial - eptacog alfa (activated) - eptacog alfa (activated) - treatment of bleeding episodes and prevention of bleeding in those undergoing surgery of invasive procedures in the following patient goups : * in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bu, * in patients with congenital haemophilia who are expected to have a high anamnestic response to factor viii or factor ix administration, * in patients with acquired haemophilia, in patients with congenital fvii deficieny, * in patients with glanzmann's thropnbastenia with antibodies to gp iib-iiia and/or hla, and with past or present refractoriness to platelet transfusions.

ישראל - עברית - Ministry of Health

novartis israel ltd - eltrombopag as olamine - טבליות מצופות פילם - eltrombopag as olamine 25 mg - eltrombopag - eltrombopag - for the treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (itp) to increase platelet count and reduce or prevent bleeding.

ישראל - עברית - Ministry of Health

novartis israel ltd - eltrombopag as olamine - טבליות מצופות פילם - eltrombopag as olamine 50 mg - eltrombopag - eltrombopag - for the treatment of previously treated patients with chronic idiopathic thrombocytopenic purpura (itp) to increase platelet count and reduce or prevent bleeding.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - folic acid - טבליה - folic acid 5 mg - folic acid - folic acid - prevention and treatment of folic acid deficiency.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 5000 iu / 0.3 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with platinum-based chemotherapy prone to induce anemia (cisplatin 75 mg/m2/cycle carboplatin: 350 mg/m2/cycle). treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - epoetin beta - תמיסה להזרקה - epoetin beta 10000 iu / 0.6 ml - erythropoietin - erythropoietin - treatment of anemia associated with chronic renal failure (renal anemia) in patients on dialysis. treatment of symptomatic renal anemia in patients not yet undergoing dialysis. increasing the yield of autologous blood from patients in a pre-donation program. its use in this indication must be balanced against the reported increased risk of thromboembolic events. treatment should only be given to patients with moderate anemia (hb 10-13 g/dl (6.21- 8.07 mmol/l) no iron deficiency) or when blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). treatment of anemia in adult patients with solid tumors and treated with chemotherapy. treatment of anemia in adult patients with multiple myeloma low grade non-hodgkin's lymphoma or chronic lymphocytic leukemia who have a relative erythropoietin deficiency* and are receiving anti-tumor therapy. * deficiency is defined as an

ישראל - עברית - Ministry of Health

j-c health care ltd - recombinant human erythropoietin - תמיסה להזרקה - recombinant human erythropoietin 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of severe anemia associated with chronic renal failure, anemia in zidovudine treated hiv infected patients, anemia in cancer patients on chemotherapy.to increase the yield of autologous blood from patients in a predonation programme initiated to avoid the use of homologous blood. treatment is indicated in patients with moderate anemia (packed cell volume (pcv) approximately 33 to 39% , no iron deficiency) if blood conserving procedures are not available or insufficient either: a: when the scheduled major elective surgery requires a large volume of blood ( 4 or more units of blood for females or 5 or more units for males) or b: when the period necessary to obtain the required volume of autologous blood is too short. perisurgery: reduction of allogeneic blood transfusion in surgery patients : eprex is indicated for the treatment of anemic patients (hemoglobin 9-11 g/dl) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions. eprex is indicat